354 related articles for article (PubMed ID: 20008302)
41. Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Lund J; Gruber A; Lauri B; Duru AD; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Carlsson C; Waage A; Gimsing P; Vangsted AJ; Frølund U; Holmberg E; Gahrton G; Alici E; Hardling M; Mellqvist UH; Nahi H
Cancer Med; 2018 Jun; 7(6):2256-2268. PubMed ID: 29673108
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.
Palumbo A; Bertola A; Falco P; Rosato R; Cavallo F; Giaccone L; Bringhen S; Musto P; Pregno P; Caravita T; Ciccone G; Boccadoro M
Hematol J; 2004; 5(4):318-24. PubMed ID: 15297848
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
Touzeau C; Blin N; Clavert A; Roland V; Loirat M; Tessoulin B; Le Gouill S; Planche L; Pennetier M; Mahe B; Mohty M; Malard F; Peterlin P; Dubruille V; Moreau P
Leuk Lymphoma; 2012 Jul; 53(7):1318-20. PubMed ID: 22211836
[TBL] [Abstract][Full Text] [Related]
44. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Rajkumar SV; Jacobus S; Callander NS; Fonseca R; Vesole DH; Williams ME; Abonour R; Siegel DS; Katz M; Greipp PR;
Lancet Oncol; 2010 Jan; 11(1):29-37. PubMed ID: 19853510
[TBL] [Abstract][Full Text] [Related]
45. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.
Harousseau JL; Dimopoulos MA; Wang M; Corso A; Chen C; Attal M; Spencer A; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
Haematologica; 2010 Oct; 95(10):1738-44. PubMed ID: 20460639
[TBL] [Abstract][Full Text] [Related]
46. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y; Kuroda J; Kaneko H; Kamitsuji Y; Fuchida SI; Nakaya A; Shibayama H; Uoshima N; Yokota I; Uchiyama H; Yagi H; Kosugi S; Matsui T; Ishikawa J; Matsuda M; Ohta K; Iida M; Tanaka H; Kobayashi M; Wada K; Shimazaki C; Nomura S; Imada K; Hino M; Matsumura I; Kanakura Y; Takaori-Kondo A;
Int J Hematol; 2018 May; 107(5):541-550. PubMed ID: 29380179
[TBL] [Abstract][Full Text] [Related]
47. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
Larocca A; Cavallo F; Mina R; Boccadoro M; Palumbo A
Future Oncol; 2012 Oct; 8(10):1223-38. PubMed ID: 23130924
[TBL] [Abstract][Full Text] [Related]
48. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Barlogie B
Semin Hematol; 2003 Oct; 40(4 Suppl 4):33-8. PubMed ID: 15015894
[TBL] [Abstract][Full Text] [Related]
49. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Gastineau DA; Litzow MR; Fonseca R; Roy V; Rajkumar SV; Gertz MA
Leukemia; 2007 Sep; 21(9):2035-42. PubMed ID: 17581613
[TBL] [Abstract][Full Text] [Related]
50. Clinical experience with thalidomide and lenalidomide in multiple myeloma.
Moehler T
Curr Cancer Drug Targets; 2012 May; 12(4):372-90. PubMed ID: 22229246
[TBL] [Abstract][Full Text] [Related]
51. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Benboubker L; Dimopoulos MA; Dispenzieri A; Catalano J; Belch AR; Cavo M; Pinto A; Weisel K; Ludwig H; Bahlis N; Banos A; Tiab M; Delforge M; Cavenagh J; Geraldes C; Lee JJ; Chen C; Oriol A; de la Rubia J; Qiu L; White DJ; Binder D; Anderson K; Fermand JP; Moreau P; Attal M; Knight R; Chen G; Van Oostendorp J; Jacques C; Ervin-Haynes A; Avet-Loiseau H; Hulin C; Facon T;
N Engl J Med; 2014 Sep; 371(10):906-17. PubMed ID: 25184863
[TBL] [Abstract][Full Text] [Related]
52. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
[TBL] [Abstract][Full Text] [Related]
53. Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Totani H; Ri M; Kato C; Nakashima T; Suzuki N; Hagiwara S; Kanamori T; Murakami S; Masuda A; Kinoshita S; Yoshida T; Narita T; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
Int J Hematol; 2016 Mar; 103(3):316-21. PubMed ID: 26715148
[TBL] [Abstract][Full Text] [Related]
54. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
[TBL] [Abstract][Full Text] [Related]
55. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
[TBL] [Abstract][Full Text] [Related]
56. Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.
Jo JC; Kang BW; Sym SJ; Lee SS; Jang G; Kim S; Lee DH; Kim SW; Lee JS; Suh C
Invest New Drugs; 2011 Feb; 29(1):175-81. PubMed ID: 19823768
[TBL] [Abstract][Full Text] [Related]
57. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A;
Blood; 2012 Jul; 120(1):9-19. PubMed ID: 22498745
[TBL] [Abstract][Full Text] [Related]
59. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
[TBL] [Abstract][Full Text] [Related]
60. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
Raja KR; Plasil M; Rihova L; Pelcova J; Adam Z; Hajek R
Cytometry B Clin Cytom; 2014 Jul; 86(4):220-8. PubMed ID: 23922218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
